A CCL2/MCP-1 antagonist attenuates fibrosis of the infrapatellar fat pad in a rat model of arthritis
We provide initial evidence that anti-CCL2 gene therapy can effectively suppress the development of IFP fibrosis in a rat model. Thus, targeting CCL2 holds promise as a therapeutic strategy for managing tissue fibrosis in osteoarthritis patients.
Authors
- Yusuke Nakagawa (ORCID: https://orcid.org/0000-0003-0170-9743)
- Takeshi Muneta (ORCID: https://orcid.org/0000-0003-1018-2939)
- Hideyuki Koga (ORCID: https://orcid.org/0000-0003-4574-1796)
- H. Yoshimura (ORCID: https://orcid.org/0000-0001-7392-9046)
Institutions
- Tokyo Medical and Dental University (JP)
- Noguchi Hospital (JP)
Publication Details
- Journal
- BMC Musculoskeletal Disorders
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1186/s12891-024-07737-y
- Citations
- 6
- Primary Topic
- Chemokine receptors and signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Japan Society for the Promotion of Science